AbbVie has rewarded shareholders again with a quarterly dividend. As a Dividend King, it is the epitome of a steady and ...
Shares in AbbVie slumped Monday after the company disclosed its psychiatric medicine emraclidine didn’t best placebo in two ...
Negative data cost AbbVie billions of dollars in market value and convinced analysts Bristol Myers had placed a better bet in ...
After being rejected twice before, AbbVie’s latest Parkinson’s drug finally has been approved by the U.S. Food & Drug Administration. Findings from clinical studies of the drug, called Vyalev ...
Zacks.com on MSN1d
AbbVie Stock Falls 11% in a Month: Should You Buy the Dip?AbbVie’s ABBV stock declined almost 11% in the past month, mainly due to a recent pipeline setback. In November, AbbVie ...
AbbVie Inc. said Thursday the Food and Drug ... based therapy for the treatment of motor fluctuations in advanced Parkinson’s disease. The treatment allows patients to have a steady flow of ...
Since then, we have seen tavapadon deliver positive phase 3 results in Parkinson's disease patients, and while I am not too ...
AbbVie has launched its Produodopa therapy for Parkinson’s disease onto the market in the EU, becoming the first and only 24-hour levodopa-based subcutaneous infusion therapy for the ...
AbbVie stock drops after emraclidine fails Phase 2 trials for schizophrenia, raising questions about its neuroscience ...
Discover how AbbVie investors that bought the anxiety over the loss of Humira exclusivity are sitting on massive gains. Read ...
AbbVie ABBV announced that the FDA has approved its subcutaneous administered drug ABBV-951 to treat motor fluctuations in adult patients with advanced Parkinson's disease (PD). The drug will be ...
With rising demand and an ageing population, European healthcare systems are under strain. In the second article in our ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback